Jazz Pharmaceuticals (JAZZ) Q1 2026 Earnings: EPS Surges Past Estimates by 36%, Stock Slips Despite Strong Beat - Revenue Warning Signal

dars.gov.et·Jun 13

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Jazz Pharmaceuticals' first quarter 2026 earnings per share exceeded estimates by 36%. Despite this strong beat, the company's stock price declined. The earnings report also included a revenue warning signal, although the company's stock has seen significant growth over the past year.

Full coverage

Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here’s What’s Driving the Move

TIKR.com·May 7

Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge

ChartMill·Jun 5

Earnings call transcript: Jazz Pharmaceuticals Q1 2026 earnings beat expectations

Investing.com·May 5

Jazz Pharmaceuticals Q1 2026 Earnings: EPS Surges Past Estimates, Stock Declines Despite Strong Beat - Guidance vs Actual

dars.gov.et·Jun 8

Jazz Pharmaceuticals (JAZZ) Q1 2026 Earnings: EPS Surges 36% Above Estimates as Stock Edges Lower - Revenue Growth Report

Bölüm Sonu Canavarı·May 29

Why Jazz Pharmaceuticals Stock’s EPS is Set to 3x in 2026

TIKR.com·Apr 11

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

Seeking Alpha·May 6

CVS Health Surged 7% After Q1 2026 Earnings. Here’s Where the Stock Could Go by 2030

TIKR.com·May 8

View original report at dars.gov.et ↗

Fetching the latest headlines…